Dr. Anita J. Chawla, Ph.D., has been a Managing Principal of Analysis Group, Inc., since October 2011. Dr. Chawla has more than 20 years' experience as a health economist. She has extensive experience using economic analyses to support the business objectives of life sciences companies. As a member of Analysis Group's Menlo Park office, Dr. Chawla has played a lead role in developing an early phase economic-modeling capability for pharmaceuticals--an approach that connects strategic planning with health economics. She has assessed the value of a wide range of therapies to inform health care decision makers such as physicians, patients, payers and policy makers. An expert in all phases of drug development, she has designed economic and outcomes research strategies for product development and commercialization objectives. Dr. Chawla has conducted research and published on a range of health economics issues, including treatment patterns and outcomes, economic burden of various illnesses, cost-effectiveness analysis in clinical trials, drug spending trends and performance measures for prescription drug management. She serves as an Independent Director of CytRx Corporation since March 9, 2015. She is a member of the American Economic Association, the American Society of Health Economists and the International Society for Pharmacoeconomics and Outcomes Research. She has served as a reviewer or referee for several journals, including Health Affairs, Journal of the American Medical Association and Journal of Business and Economic Statistics. Prior to joining Analysis Group, Dr. Chawla served as the Director of health economics and outcomes research at Genentech, Inc. She received her Ph.D. in economics from the University of Michigan and her B.A. in economics and political science from Wellesley College.
Reimbursement: The Best-Laid Plans?
3:40 PM - 4:30 PM